Revista da Sociedade Brasileira de Medicina Tropical · 2006
Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mayrink Wilson, Botelho Ana Cristina de Carvalho, Magalhães Paulo Araújo, Batista Sebastião Mariano, Lima Antonio de Oliveira, Genaro Odair, Costa Carlos Alberto da, Melo Maria Norma de, Michalick Marilene Susan Marques, Williams Paul, Dias Magno, Caiaffa Waleska Teixeira, Nascimento Evaldo do, Machado-Coelho George Luiz Lins
Аннотация
The first choice of treatment for American cutaneous leishmaniasis is the pentavalent antimonial drug. Although it has been shown that this treatment is mostly effective and indicated, some disadvantages should be taken into account such as side effects, long term treatment inconveniences and counter-indication for patients suffering from cardiopathy, nephropathy; yet, aging, pregnancy and other conditions. With the advent of the vaccine anti-American cutaneous leishmaniasis as a prophylactic measure, studies on therapy using the vaccine associated or not with other drugs have been performed by many investigators and it is currently among the alternative treatments and prevention measures for American cutaneous leishmaniasis. In conclusion, the association between antimony and vaccine (immunochemotherapy) showed the same cure rate when compared with the standard treatment (100%) and it was also able to reduce the salt volume in 17.9% and treatment length from 87 to 62 days, decreasing side effects.